The single study provided does not actually investigate Lactobacillus gasseri or H. pylori; it examines cross-reactive antibodies between gut commensal bacteria and SARS-CoV-2, along with potential interactions between gut microbiome composition and COVID-19 vaccination responses. Because none of the linked research addresses Lactobacillus gasseri in the context of H. pylori support, no evidence-based summary on that specific topic can be drawn from the materials provided. Readers interested in this subject would need to consult studies that directly examine Lactobacillus gasseri supplementation alongside H. pylori eradication therapy or infection outcomes. The mismatch between the requested topic and the supplied research prevents a responsible synthesis from being offered here.
Citations from PubMed and preprint sources. Match score (0-100) reflects automated search ranking, not clinical appraisal.
| Title | Type | Year | Direction | Match |
|---|---|---|---|---|
| Pre-existing antibodies targeting a linear epitope on SARS-CoV-2 S2 cross-rea... | Other | 2021 | Neutral | 90 |